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Benefit of early initiation of intensive lipid lowering 
treatment is established in patients with acute coronary 
syndrome (ACS). Cholesterol-independent, pleiotropic 
effects of statin have been widely investigated with regard 
to suppression of plaque vulnerability (1). Previous studies 
explored favorable mechanisms of early initiation of statin 
with plaque modification by reduction of necrotic core in 
plaques with high risk morphology (2), or in plaques with 
ACS (3). The other mechanisms including inhibition of 
inflammatory activity, reduction of lipid accumulation in the 
plaque, and improving endothelial function have been also 
suggested as statin effects (4). In the MIRACL (Myocardial 
Ischemia Reduction with Aggressive Cholesterol Lowering) 
study, administration of 80 mg atorvastatin within 24 to 
96 hours of hospital, compared with placebo, reduced 
the incidence of cardiovascular events (14.8% vs. 17.4%, 
relative risk 0.84, P=0.048) including death, myocardial 
infarction, cardiac arrest with resuscitation, and recurrent 
ischemic symptom within 16 weeks in patients with ACS (5). 
Compared with moderate intensity, 40 mg pravastatin, 80 mg 
atorvastatin achieved lower density lipoprotein cholesterol 
(LDL-C) in patients hospitalized for ACS, which brought 
favorable clinical outcomes with 16% reduction in major 
cardiovascular events for 2 years in the PROVE IT-TIMI 
22 (Pravastatin or Atorvastatin Evaluation and Infection 
Therapy–Thrombolysis in Myocardial Infarction 22) 
study (6). The IMPROVE-IT (Improved Reduction of 
Outcomes: Vytorin Efficacy International Trial) study 
compared simvastatin plus additional ezetimibe with 
simvastatin monotherapy (7). Simvastatin-ezetimibe 
combination was more effective in reducing average 
LDL-C level than simvastatin monotherapy and it resulted 
in lower incidences of primary end point [32.7% vs. 34.7%, 
hazard ratio (HR) 0.94, P=0.016] during 7-year follow-
up. Current US and European guidelines have emphasized 
the importance of intensive lipid lowering, which is 
one of cornerstones for management of atherosclerotic 
coronary artery disease especially in high risk patients, with 
using high intensity statin or achieving very low LDL-C 
concentration (8-12).
Concept of early initiation of statin has been accepted 
as a manner of starting statin treatment in a patient with 
stable condition before discharge after index ACS event 
(8,10). There have been also concerns about safety of high 
intensity statin administration during early (or unstable) 
phase of ACS. More importantly, definite evidences 
supporting administration of statin at very early phase of 
ACS or before invasive management are limited. Previous 
trials assessing early lipid lowering strategies enrolled 
patients during in-hospital period after index ACS event. 
The MIRACL trial allowed randomization between 1 and 
3 days after admission, however, it only included patients 
with non-ST elevation ACS not planning to undergo 
coronary revascularization. In both PROVE-IT and 
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IMPROVE-IT trials including nearly 70% of patients 
undergoing PCI for treatment of index event, subjects were 
allowed to be enrolled within 10 days after onset of ACS 
events and before discharge. The studies tested in-hospital 
initiation of statin defined by the study protocol and 
demonstrated meaningful results in favor of more potent 
lipid lowering treatment. Study protocol of the trials seem 
to be pragmatic that majority of patients with ACS may be 
considered for invasive management and that there was no 
reason to avoid statin initiation for stabilized patients after 
PCI in clinical practice. However, it had not been revealed 
whether initiation of statin before PCI or very early phase 
after event onset may be beneficial or harmful in patients 
with ACS.
Recently published study, the SECURE-PCI (Statins 
Evaluation in Coronary Procedures and Revascularization) 
trial was designed to assess the effect of periprocedural 
administration of statin in patients with ACS and planned 
coronary revascularization (13). The investigators sought 
to test an interesting hypothesis whether high dose 
atorvastatin before invasive management may reduce 
adverse cardiac events in ACS. Patients were randomized to 
receive either loading doses of 80 mg atorvastatin (n=2,087) 
or placebo (n=2,104) between 2 to 12 hours before PCI and 
next day, and were to receive 40 mg atorvastatin for 30 days 
afterward. There was no significant difference in primary 
outcome, defined as major adverse cardiovascular events 
including all-cause death, myocardial infarction, stroke, 
and unplanned coronary revascularization within 30 days, 
which was occurred in 6.2% in atorvastatin group, and 
7.1% in placebo group (HR 0.88, P=0.27). It seems clear 
that no significant benefit of preprocedural administration 
of loading dose of atorvastatin compared with control 
treatment (initiation of 40 mg atorvastatin at day 2 after 
PCI). Even though assumption of the trial was not satisfied, 
its overall result has valuable implications in clinical 
practice: (I) after available evidences, there is no question 
about that intensive lipid lowering treatment should be 
started before discharge or within 10 days after ACS events; 
(II) initiation of high intensity statin within 2 days after PCI 
is as effective as its initiation within 12 hours before PCI in 
patients planning PCI. Clinicians do not have to be hasty in 
initiation of high intensity statin if the timing is just before 
revascularization; (III) inversely, there seems to be no need 
to defer preprocedural initiation of high intensity statin—
loading dose of atorvastatin before PCI was not associated 
with periprocedural complications or increasing risk of 
adverse cardiovascular events.
However, there are still some questions remained. 
The trial compared timing of statin initiation between 
relatively narrow time window, 2 days beyond invasive 
procedure. Current evidences strongly support early 
initiation of intensive lipid lowering with statin, however 
the timing has not been definitely determined. It is not 
clear if it is equivalently effective to start statin as discharge 
prescription compared with administration at the earliest 
timing after event. Even though majority of eligible studies 
were conducted with small number of patients or with 
stable patients, patient-level meta-analysis of randomized 
controlled trials supported benefit of preprocedural initiation 
of high dose statin in patients with planned PCI (14). 
Another meta-analysis of randomized controlled trials in 
patients with ACS undergoing PCI demonstrated study-level 
association between earlier timing of statin initiation and 
greater clinical benefit within 30 days (15). Despite negative 
result of primary outcome, the SECURE-PCI study also 
remains a question if preprocedural administration of high 
intensity statin may be beneficial in patients undergoing 
PCI. To understand the role of high intensity statin is still 
challenging in the patients with unstabilized condition as well 
as those undergoing PCI after ACS.
Our institute previously reported results of two 
randomized controlled trials assessing preprocedural 
high intensity statin at emergency room before PCI. The 
STATIN STEMI (Efficacy of High-Dose AtorvaSTATIN 
Loading Before Primary Percutaneous Coronary 
Intervention in ST-Elevation Myocardial Infarction) study 
compared an effect of 80 mg atorvastatin versus 10 mg 
atorvastatin before PCI with total 171 patients with ST 
elevation myocardial infarction. Although study population 
was limited to reveal statistical significance of differences 
in major clinical outcomes, a meaningful improvement in 
immediate coronary flow was noted with high intensity 
statin treatment before the procedure (16). Another study 
compared 40 mg rosuvastatin versus placebo as a loading 
dose before PCI and daily maintenance doses for following 
7 days. However, it did not show significant differences in 
periprocedural coronary flow, infarct burden on cardiac 
magnetic resonance imaging, or clinical outcomes (17). 
Considering our clinical experiences and available evidences, 
we have an insight that initiation of high intensity statin 
at earlier time during in-hospital management is mostly 
feasible (even in the setting of urgent or emergency PCI) 
and not associated with increasing adverse events at worst. 
We have not hesitated to initiate prescription of high 
intensity statin in the management of ACS, irrespective of 
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the timing of PCI, when a patient is available to take oral 
medication. There is no reason to defer statin treatment 
at the earliest time after ACS event based on current 
evidences.
Findings of the SECURE-PCI trial support current 
strategies for management after ACS with early initiation 
of high intensity statin. It also implies that periprocedural 
administration of high intensity statin before invasive 
management would be acceptable without harm in PCI-
eligible patients with ACS. Further investigations are required 
to clarify whether or how earlier statin initiation has an effect 
on better clinical outcomes and whether preprocedural high 
intensity statin truly affect clinical benefits in patients treated 
by invasive revascularization for ACS.
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